mRNA-1010 shows superior efficacy against influenza in older adults

A phase 3 randomized controlled trial evaluated the trivalent mRNA-1010 vaccine (37.5 µg) against a licensed standard-dose comparator in 40,703 adults aged 50 years or older. The primary outcome was relative vaccine efficacy against RT-PCR-confirmed, protocol-defined influenza-like illness caused by influenza A or B over a follow-up period of 181 days. The mRNA-1010 group showed a 26.6% relative vaccine efficacy (95% CI, 16.7 to 35.4), with 2.0% incidence versus 2.8% in the comparator group, demonstrating statistical superiority.

The absolute numbers were 411 of 20,179 recipients in the mRNA-1010 group and 557 of 20,124 in the standard-dose comparator group. This translates to a number needed to treat that favors the mRNA vaccine for preventing influenza-like illness in this older population. The study's design as a large, multicenter trial enhances the generalizability of these findings to similar adult populations.

Safety profiles showed higher rates of common adverse events with mRNA-1010: injection-site pain (65.8% vs 29.8%), fatigue (45.1% vs 20.3%), headache (37.8% vs 18.0%), and myalgia (35.4% vs 11.6%). Serious adverse events were low and comparable between groups (2.2% vs 1.9%), with few considered vaccine-related. Most reactions were mild to moderate and transient, supporting the vaccine's tolerability.

Limitations include the lack of reported publication type and setting details, which may affect contextual interpretation. The study was funded by Blackstone Life Sciences and Moderna, a potential conflict of interest that warrants consideration. The follow-up period of 181 days covers a typical influenza season but may not capture longer-term efficacy or safety.

For healthcare providers, these results support the use of mRNA-1010 as an effective option for seasonal influenza prevention in adults 50 years and older. The superior efficacy and manageable safety profile make it a viable alternative to standard vaccines. Clinicians should discuss the higher reactogenicity with patients, emphasizing that most side effects are transient.

The trial's phase 3 status and large sample size provide robust evidence for regulatory and clinical decision-making. However, practice relevance was not reported, so integration into guidelines may require further evaluation. The absence of secondary outcomes in the input limits a fuller efficacy assessment, but the primary outcome is clinically meaningful.

In summary, mRNA-1010 demonstrates a significant relative efficacy advantage over standard comparator in older adults, with a safety profile consistent with other mRNA vaccines. This supports its potential role in improving influenza prevention strategies for aging populations.